A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
Clinical trial NCT00249808 · COMPLETED
Trial details
- NCT number
- NCT00249808
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2004-12-13
- Primary completion
- 2007-01-25
- Enrollment
- 1266
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.